FILING ANALYSIS · TUESDAY, NOVEMBER 10
Coya Therapeutics, Inc. COYA — 8-K: Results of Operations and Financial Condition
neutral
Coya Therapeutics reports Q3 financial results with a net loss of $10.6 million and announces the completion of enrollment in its Phase 2/3 ALSTARS trial, with topline data anticipated in early Q2 2027. The company has sufficient cash to fund operations past the trial's topline data readout and into the second half of 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →